证券研究报告 | 行业周报 2024年 03月 25日 家电 石头科技将发布全新 V20 系列扫地机 ——家电 2024 年第 12 周周报 股票 股票 投资 EPS （元） PE 强于大市（维持评级） 代码 名称 评级 2023E 2024E 2023E 2024E 002011.SZ 盾安环境 增持 0.65 0.84 18.52 14.33 家电 沪深300 002050.SZ 三花智控 增持 0.82 1.02 29.93 24.06 14% 600690.SH 海尔智家 增持 1.8 2.05 12.97 11.39 9% 603868.SH 飞科电器 增持 2.34 2.6 20.47 18.42 4% -1% 688007.SH 光峰科技 买入 0.39 0.57 48.26 33.02 -6% 688169.SH 石头科技 买入 15.29 18.03 21.34 18.1 -11% 689009.SH 九号公司 买入 7.99 11.59 3.82 2.63 -16% 资料来源：长城证券产业金融研究院，注：标*公司2023年EPS为实际值 -21% 2023-03 2023-07 2023- ...

Investment Rating - The report maintains a "Buy" rating for Wanhua Chemical, expecting the stock price to outperform the industry index by over 15% in the next six months [4][15]. Core Views - Wanhua Chemical's leading position in the polyurethane industry remains solid, with continuous growth in both petrochemical and new materials sectors [2][9]. - The company achieved steady revenue growth in 2023, with total revenue of 175.36 billion yuan, a year-on-year increase of 5.92% [1][2]. - The report highlights the company's ongoing capacity expansion and its strategic acquisitions, which are expected to enhance its market position and profitability [7][9]. Financial Summary - **Revenue and Profitability**: - 2023 revenue was 175.36 billion yuan, with a net profit of 16.82 billion yuan, reflecting a 3.59% increase year-on-year [1]. - Projected revenues for 2024, 2025, and 2026 are 197.41 billion yuan, 224.10 billion yuan, and 252.86 billion yuan, respectively, with expected growth rates of 12.6%, 13.5%, and 12.8% [1][9]. - **Earnings Per Share (EPS)**: - The EPS for 2023 was 5.36 yuan, with projections of 5.88 yuan, 7.24 yuan, and 8.24 yuan for the years 2024, 2025, and 2026, respectively [1][9]. - **Profit Margins**: - The gross margin for 2023 was 16.79%, showing a slight increase of 0.22 percentage points year-on-year [3]. - The net profit margin was 10.44%, up by 0.15 percentage points year-on-year [3]. Segment Performance - **Polyurethane Segment**: - Revenue from the polyurethane segment was 67.39 billion yuan, with a year-on-year growth of 7.14% [2]. - The segment's sales volume increased by 16.93% to 489,000 tons [2]. - **Petrochemical Segment**: - Revenue from the petrochemical segment was 69.33 billion yuan, with a slight decline of 0.44% year-on-year [2]. - The sales volume for this segment grew by 4.02% to 472,000 tons [2]. - **Fine Chemicals and New Materials**: - This segment generated 23.90 billion yuan in revenue, marking an 18.45% increase year-on-year [2]. - The sales volume surged by 67.84% to 159,000 tons [2]. Capacity Expansion and Strategic Initiatives - The company has completed acquisitions and expansions, including a new TDI production facility in Xinjiang and capacity upgrades in its existing plants [7][9]. - Wanhua Chemical is the largest global supplier of MDI and TDI, with a total MDI capacity of 3.1 million tons per year and TDI capacity of 950,000 tons per year [7][9]. - The report emphasizes the company's integrated petrochemical operations, which enhance its competitive edge and overall value [8][9].

证券研究报告 | 公司动态点评 2024 年 03月 27日 神火股份（000933.SZ） 2023 年价格下跌拖累业绩，静待铝业务释放弹性 财务指标 2022A 2023A 2024E 2025E 2026E 买入（首次评级） 营业收入（百万元） 42,704 37,625 39,669 42,380 44,954 股票信息 增长率yoy（%） 23.8 -11.9 5.4 6.8 6.1 归母净利润（百万元） 7,578 5,905 6,283 6,825 7,348 行业 有色金属 增长率yoy（%） 134.1 -22.1 6.4 8.6 7.6 2024年3月26日收盘价（元） 19.74 ROE（%） 40.5 27.7 24.1 21.5 19.5 总市值（百万元） 44,409.24 EPS最新摊薄（元） 3.37 2.62 2.79 3.03 3.27 流通市值（百万元） 44,187.31 P/E（倍） 5.9 7.5 7.1 6.5 6.0 总股本（百万股） 2,249.71 P/B（倍） 2.8 2.2 1.8 1.5 1.2 流通股本（百万股） 2,238.47 资料来源：公司财报 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for the stock price over the next six months [1][6][11] Core Insights - The company achieved a significant turnaround in 2023, reporting a revenue of $85.58 million, a year-on-year growth of 19.75%, and a net profit of $2.81 million, reflecting a 114.16% increase compared to the previous year [1][2] - The recovery in the international data connectivity business, particularly in China and Japan, has been a key driver of growth, alongside the expansion of new business applications in IoT and data connectivity solutions [2][3] - The company is actively promoting new application scenarios and products, aiming to enhance user experience and expand market share, with a focus on integrating technology into daily life [3] Financial Summary - Revenue projections for 2024 are estimated between $95 million and $112 million, representing a year-on-year growth of 11.0% to 30.8% [3] - The company expects to generate a net profit of $5.29 million in 2024, with EPS forecasted at $0.14 [6] - The financial metrics indicate a positive trend, with a projected ROE of 24.80% in 2024 and a decreasing P/E ratio from 22.89 in 2023 to 12.16 in 2024 [1][6]

证券研究报告 | 公司动态点评 2024 年 03月 27日 美光科技（MU.O） FY2024 Q2 业绩超预期，HBM3E 量产出货助力业绩增长 财务指标 FY2022A FY2023A FY2024E FY2025E FY2026E 增持（维持评级） 营业收入（百万美元） 30,758 15,540 21,225 28,298 37,077 股票信息 增长率yoy（%） 11.0 -49.5 36.6 33.3 31.0 净利润（百万美元） 8,687 -5,833 1,097 3,470 5,072 行业 电子 增长率yoy（%） 48.2 -167.1 118.8 216.4 46.2 收盘价（元） 118.80 ROE（%） 17.4 -13.2 2.4 7.1 9.4 总市值（百万元） 121644.38 EPS最新摊薄（美元） 7.84 -5.27 0.99 3.13 4.58 流通市值（百万元） 121644.38 P/E（倍） 15.1 -22.6 119.9 37.9 25.9 总股本（百万股） 1107.00 P/B（倍） 2.6 3.0 2.9 2.7 2.4 流通股本（百万股） 1 ...

免责声明 长城证券股份有限公司（以下简称长城证券）具备中国证监会批准的证券投资咨询业务资格。 长城证券在法律允许的情况下可参与、投资或持有本报告涉及的证券或进行证券交易，或向本报告涉及的公司提供或争取提供包括投资 银行业务在内的服务或业务支持。长城证券可能与本报告涉及的公司之间存在业务关系，并无需事先或在获得业务关系后通知客户。 长城证券版权所有并保留一切权利。 长城证券产业金融研究院 地址：上海市浦东新区世博馆路 200 号 A 座 8 层 传真：021-31829681 深圳 北京 传真：86-10-88366686 作者 -40% -20% 0 % 20% 40% 60% 80% 100% 120% PDD.O IXIC.GI 邮编：200126 拼多多（PDD.O） 23Q4 及 2023 年度业绩点评:国内主站及海外业务齐头并进，持续 推动高质量发展 | --- | --- | --- | --- | --- | --- | --- | --- | |----------------------|---------|---------|---------|---------|---------|-- ...

证券研究报告 | 公司动态点评 2024 年 03月 26日 珍酒李渡（06979.HK） 增长高质量，势能正当时 财务指标 2022A 2023A 2024E 2025E 2026E 买入（维持评级） 营业收入（百万元） 5856 7030 8540 10302 12159 股票信息 增长率yoy（%） 14.8 20.1 21.5 20.6 18.0 归母净利润（百万元） 1029.87 2327.08 2028.61 2543.45 3088.50 行业 食品饮料 增长率yoy（%） -0.2 126.0 -12.8 25.4 21.4 2024年3月26日收盘价（港元） 10.900 ROE（%） -27.0 18.4 13.8 14.7 15.2 总市值（百万港元） 36,936.00 EPS最新摊薄（元） 0.30 0.69 0.60 0.75 0.91 流通市值（百万港元） 36,936.00 P/E（倍） 35.9 15.9 18.2 14.5 12.0 总股本（百万股） 3,388.62 P/B（倍） -9.7 2.9 2.5 2.1 1.8 流通股本（百万股） 3,388.62 资料来源： ...

长城证券在法律允许的情况下可参与、投资或持有本报告涉及的证券或进行证券交易，或向本报告涉及的公司提供或争取提供包括投资 银行业务在内的服务或业务支持。长城证券可能与本报告涉及的公司之间存在业务关系，并无需事先或在获得业务关系后通知客户。 长城证券版权所有并保留一切权利。 特别声明 《证券期货投资者适当性管理办法》、《证券经营机构投资者适当性管理实施指引（试行）》已于 2017 年 7 月 1 日 起正式实施。因本研 究报告涉及股票相关内容，仅面向长城证券客户中的专业投资者及风险承受能力为稳健型、积极型、激进型的普通投资者。若您并非上 述类型的投资者，请取消阅读，请勿收藏、接收或使用本研究报告中的任何信息。 因此受限于访问权限的设置，若给您造成不便，烦请见谅！感谢您给予的理解与配合。 分析师声明 本报告署名分析师在此声明：本人具有中国证券业协会授予的证券投资咨询执业资格或相当的专业胜任能力，在执业过程中恪守独立诚 信、勤勉尽职、谨慎客观、公平公正的原则，独立、客观地出具本报告。本报告反映了本人的研究观点，不曾因，不因，也将不会因本 报告中的具体推荐意见或观点而直接或间接接收到任何形式的报酬。 投资评级说明 | ...

证券研究报告 | 公司动态点评 2024 年 03月 26日 金盘科技（688676.SH） 国内外产品需求高增，数字化赋能内生动力 财务指标 2022A 2023A 2024E 2025E 2026E 增持（维持评级） 营业收入（百万元） 4,746 6,668 9,585 12,725 15,106 股票信息 增长率yoy（%） 43.7 40.5 43.8 32.8 18.7 归母净利润（百万元） 283 505 780 1,073 1,360 行业 电力设备及新能源 增长率yoy（%） 20.7 78.2 54.5 37.6 26.7 2024年3月26日收盘价（元） 42.60 ROE（%） 9.9 15.2 20.1 22.2 22.5 总市值（百万元） 18,205.64 EPS最新摊薄（元） 0.66 1.18 1.82 2.51 3.18 流通市值（百万元） 18,205.64 P/E（倍） 64.6 36.2 23.5 17.0 13.5 总股本（百万股） 427.36 P/B（倍） 6.8 5.8 4.9 3.9 3.1 流通股本（百万股） 427.36 资料来源：公司财报，长城证券产业 ...

Investment Rating - The report assigns a "Buy" rating for the company, indicating an expected stock price increase of over 15% relative to the industry index within the next six months [13]. Core Insights - The company has a strong brand advantage and has been developing for nearly 30 years, focusing on the production and sales of pharmaceuticals in pediatric, oral, respiratory, digestive, and gynecological fields [1]. - The company is expected to achieve steady revenue growth driven by its core products, with projected revenues of 95.72 billion yuan, 100.40 billion yuan, and 113.32 billion yuan for 2023, 2024, and 2025 respectively [8]. - The company emphasizes both internal growth through R&D and external growth through product acquisitions, aiming to enrich its product pipeline [2][5]. Financial Performance - The company's revenue for 2023 is estimated at 9,572 million yuan, with a year-on-year growth rate of 6.4% [1]. - The net profit attributable to the parent company is projected to be 2,582 million yuan in 2023, reflecting an 18.9% year-on-year growth [1]. - The company maintains a high return on equity (ROE) of 19.1% for 2023, with an expected decline to 18.0% in 2024 [1]. Product Highlights - The core products include "Pudilan Xiaoyan Oral Liquid" and "Xiaoer Chiqiao Qingre Granules," which have significant market shares in their respective segments [2]. - The company has seen substantial revenue growth in its pediatric products, with "Xiaoer Chiqiao Qingre Granules" achieving a revenue increase of 42.62% from 2021 to 2022 [2]. - The introduction of innovative drugs such as PDE4 inhibitors and a new oral formulation for flu treatment is expected to enhance the company's competitive edge in the immunology and digestive fields [7][8]. Market Opportunities - The report highlights a significant market opportunity in the pediatric growth hormone deficiency (PGHD) sector, with only 5.7% of patients currently receiving treatment, indicating unmet clinical needs [6]. - The market for recombinant human growth hormone in China is projected to grow from 4 billion USD in 2017 to 26 billion USD by 2025, with a compound annual growth rate (CAGR) of 15.6% [6]. - The company is positioned to capitalize on the growing demand for long-acting recombinant growth hormones, which are expected to offer better patient compliance and treatment outcomes [6].